Central nervous system or brain metastases traditionally occur in 10-16% of metastatic breast cancer patients and are associated with a dismal prognosis. The development of brain metastases has been associated with young age, and tumors that are estrogen receptor negative, Her-2+ or of the basal phenotype. Diagnosis can be done through MRI (magnetic resonance imaging) study of the brain.In rare cases, biopsies are performed to confirm the diagnosis.
Brain Metastasis from Breast Cancer Pipeline Insight, 2023 report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Brain Metastasis from Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request for sample report here: https://www.delveinsight.com/sample/brain-metastasis-from-breast-cancer-pipeline-insight
Brain Metastasis from Breast Cancer Phases
DelveInsight’s Brain Metastasis from Breast Cancer pipeline report covers around 10+ products under different phases of clinical development like
Brain Metastasis from Breast Cancer Drugs Pipeline:
ANG-1005 is a peptide-drug conjugate containing paclitaxel covalently linked to a peptide (Angiopep-2). The drug gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the Blood brain barrier. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain. A Phase III clinical trial is evaluating ANG-1005 to treat brain metastasis associated with breast cancer.
Pembrolizumab: Merck Sharp & Dohme
Pembrolizumab is a medication used in the management and treatment of various oncologic conditions. It is in the cancer immunotherapy class of drugs. KEYTRUDA binds to the PD-1 receptor, blocking both immune-suppressing ligands, PD‑L1 and PD‑L2, from interacting with PD-1 to help restore T-cell response and immune response. The drug is currently being evaluated in Phase I/II stage of development for the treatment of patients with Brain Metastases In Breast Cancer Patients.
Key Brain Metastasis from Breast Cancer companies:
Some of the companies working in the market are Angiochem Inc, Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criterium, Inc., Bristol-Myers Squibb, Bayer, Northwest Biotherapeutics, Array BioPharma and others.
Current Brain Metastasis from Breast Cancer Treatment Scenario and Brain Metastasis from Breast Cancer Emerging Therapies:
Table of Contents:
Brain Metastasis from Breast Cancer: Overview
Late Stage Products (Phase III)
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug Name: Company Name
Early stage products (Phase I)
Brain Metastasis from Breast Cancer Key Companies
Brain Metastasis from Breast Cancer Key Products
Brain Metastasis from Breast Cancer- Unmet Needs
Brain Metastasis from Breast Cancer- Market Drivers and Barriers
Brain Metastasis from Breast Cancer- Future Perspectives and Conclusion
Brain Metastasis from Breast Cancer Analyst Views
Age Related Vision Dysfunction Market
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting/conference-coverage-services